Literature DB >> 19174155

Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase.

Julie A Heck1, Xiao Meng, David N Frick.   

Abstract

Cyclophilins are cellular peptidyl isomerases that have been implicated in regulating hepatitis C virus (HCV) replication. Cyclophilin B (CypB) is a target of cyclosporin A (CsA), an immunosuppressive drug recently shown to suppress HCV replication in cell culture. Watashi et al. recently demonstrated that CypB is important for efficient HCV replication, and proposed that it mediates the anti-HCV effects of CsA through an interaction with NS5B [Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 2005;19:111-22]. We examined the effects of purified CypB proteins on the enzymatic activity of NS5B. Recombinant CypB purified from insect cells directly stimulated NS5B-catalyzed RNA synthesis. CypB increased RNA synthesis by NS5B derived from genotype 1a, 1b, and 2a HCV strains. Stimulation appears to arise from an increase in productive RNA binding. NS5B residue Pro540, a previously proposed target of CypB peptidyl-prolyl isomerase activity, is not required for stimulation of RNA synthesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174155      PMCID: PMC2656422          DOI: 10.1016/j.bcp.2008.12.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  22 in total

1.  Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.

Authors:  Mina Nakagawa; Naoya Sakamoto; Yoko Tanabe; Tomoyuki Koyama; Yasuhiro Itsui; Yoshie Takeda; Cheng-Hsin Chen; Sei Kakinuma; Shinya Oooka; Shinya Maekawa; Nobuyuki Enomoto; Mamoru Watanabe
Journal:  Gastroenterology       Date:  2005-09       Impact factor: 22.682

Review 2.  Global epidemiology of hepatitis C virus infection.

Authors:  Colin W Shepard; Lyn Finelli; Miriam J Alter
Journal:  Lancet Infect Dis       Date:  2005-09       Impact factor: 25.071

3.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase.

Authors:  Koichi Watashi; Naoto Ishii; Makoto Hijikata; Daisuke Inoue; Takayuki Murata; Yusuke Miyanari; Kunitada Shimotohno
Journal:  Mol Cell       Date:  2005-07-01       Impact factor: 17.970

4.  Diverse effects of cyclosporine on hepatitis C virus strain replication.

Authors:  Naoto Ishii; Koichi Watashi; Takayuki Hishiki; Kaku Goto; Daisuke Inoue; Makoto Hijikata; Takaji Wakita; Nobuyuki Kato; Kunitada Shimotohno
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.

Authors:  Feng Yang; Jason M Robotham; Heather B Nelson; Andre Irsigler; Rachael Kenworthy; Hengli Tang
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

6.  A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase.

Authors:  Sreedhar Chinnaswamy; Ian Yarbrough; Satheesh Palaninathan; C T Ranjith Kumar; Vinodhini Vijayaraghavan; Borries Demeler; Stanley M Lemon; James C Sacchettini; C Cheng Kao
Journal:  J Biol Chem       Date:  2008-04-28       Impact factor: 5.157

7.  The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

Authors:  Jan Paeshuyse; Artur Kaul; Erik De Clercq; Brigitte Rosenwirth; Jean-Maurice Dumont; Pietro Scalfaro; Ralf Bartenschlager; Johan Neyts
Journal:  Hepatology       Date:  2006-04       Impact factor: 17.425

8.  Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes.

Authors:  Julie A Heck; Angela M I Lam; Nirupama Narayanan; David N Frick
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

9.  Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.

Authors:  John M Robida; Heather B Nelson; Zhe Liu; Hengli Tang
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

10.  The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication.

Authors:  Brett D Lindenbach; Béla M Prágai; Roland Montserret; Rudolf K F Beran; Anna M Pyle; François Penin; Charles M Rice
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

View more
  11 in total

Review 1.  Anti-HCV drugs in the pipeline.

Authors:  Priscilla L Yang; Min Gao; Kai Lin; Qingsong Liu; Valerie A Villareal
Journal:  Curr Opin Virol       Date:  2011-11-13       Impact factor: 7.090

Review 2.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 3.  Development of novel antiviral therapies for hepatitis C virus.

Authors:  Kai Lin
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

4.  Cyclophilin inhibitors as a novel HCV therapy.

Authors:  Hengli Tang
Journal:  Viruses       Date:  2010-08-05       Impact factor: 5.818

5.  The role of immunophilins in viral infection.

Authors:  Sam Hopkins; Philippe A Gallay
Journal:  Biochim Biophys Acta       Date:  2014-11-18

6.  Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.

Authors:  Artur Kaul; Sarah Stauffer; Carola Berger; Thomas Pertel; Jennifer Schmitt; Stephanie Kallis; Margarita Zayas; Margarita Zayas Lopez; Volker Lohmann; Jeremy Luban; Ralf Bartenschlager
Journal:  PLoS Pathog       Date:  2009-08-14       Impact factor: 6.823

7.  Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A.

Authors:  Fiona Fernandes; Israr-ul H Ansari; Rob Striker
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

8.  Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.

Authors:  Claire Rosnoblet; Bernd Fritzinger; Dominique Legrand; Hélène Launay; Jean-Michel Wieruszeski; Guy Lippens; Xavier Hanoulle
Journal:  J Biol Chem       Date:  2012-11-14       Impact factor: 5.157

Review 9.  Is there a role for cyclophilin inhibitors in the management of primary biliary cirrhosis?

Authors:  Shawn T Wasilenko; Aldo J Montano-Loza; Andrew L Mason
Journal:  Viruses       Date:  2013-01-24       Impact factor: 5.048

Review 10.  Curing a viral infection by targeting the host: the example of cyclophilin inhibitors.

Authors:  Kai Lin; Philippe Gallay
Journal:  Antiviral Res       Date:  2013-04-08       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.